Nerviano Medical Sciences S.r.l.

Pharmacia & Upjohn

Farmitalia Carlo Erba S.r.l.

Newron Pharmaceuticals S.p.a.

Pharmacia Italia S.p.a.

Axxam S.p.a.

The University of Texas System

Golgi Neurosciences S.r.l.

Other

Pharmacia & Upjohn Company

Pfizer Italia S.r.l.

Centro Nacional De Investigaciones Oncologicas (Cnio)

Breye Therapeutics Aps

Pharmacia & Tubjohn Spa

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Paolo Pevarello

Mario Varasi

Anna Vulpetti

Maria Gabriella Brasca

Gabriella Traquandi

Daniele Fancelli

Raffaella Amici

Paolo Orsini

Manuela Villa

Achille Panzeri

Paola Vianello

Francesca Quartieri

Paolo Polucci

Ron Ferguson

Roberto D'Alessio

Alberto Bonsignori

Fulvia Roletto

Patricia Salvati

Marcella Nesi

Philippe L Dostert

Russell Thomas

Patrick Roussel

Fabrizio Orzi

Valentina Cusano

Francesco Piscitelli

Ali Munaim Yousif

Domenica Torino

Philip Jones

Antonio Giordani

Antonio Longo

Carmela Speciale

Franco Heidempergher

Antonella Isacchi

Martha A Warpehoski

William J Ray

Chiara Liberati

Silvia Bovolenta

Adolfo Prandi

Romeo Roncucci

Yaima Luzardo Lightfoot

Edward L Fritzen

Betsy S Pierce

Mary Hamby

Claes Post

Barbara Salom

Pierfausto Seneci

Cristina Pesenti

Rocco Vitalone

Valeria Pittal&agrave;

Stefan Lohmer

Chiara Llberati

Tiziano Bandiera

Andrea Lombardi Borgia

Enrico Pesenti

Ettore Perrone

Ciro Mercurio

Mauro Angiolini

Sten Christian Orrenius

Roberto Maj

Jay Aaron Bertrand

Claudia Piutti

Ana Maria Garcia Collazo

Ana Belen Garcia Garcia

Maria Grazia Porro

Andrew Griffin

Mariangela Sodano

Elda Severi

Maria Grabriella Brasca

Oleksii Artamonov

Roberto D'alessio

Ana Belén GARCÍA GARCÍA

Ana María GARCÍA Collazo

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Bicyclic CX3CR1 receptor agonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and to a process for the preparation of the compounds: Ris independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring. Ris independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C-Calkyl, alkenyl or alkynyl chain. n is 1 or 2; preferably n is 1. m is 0, 1 or 2; preferably m is 0. Rand Rcan be, independently, &#x2014;H, &#x2014;F, C-Calkyl, &#x2014;OH, &#x2014;OC-Calkyl; preferably they are both &#x2014;H. X is O or S. Ris &#x2014;H or &#x2014;CHoptionally substituted by one or more fluorine atoms; preferably Ris hydrogen. The compounds can be used in the treatment of conditions or diseases mediated by P2X7 receptor.

Heterocyclic P2X7 antagonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

Substituted pyrazoles FFA4/GPR120 receptor agonists

The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. 

Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties:  The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

Substituted thiazole or oxazole P2X7 receptor antagonists

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. 

Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R, R, R, R, Rand Rhave the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. 

Fluorinated arylalkylaminocarboxamide derivatives

A compound having formula (I): wherein: R, A, Rand R, are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof, as Kinase inhibitors. 

Bicyclo-pyrazoles active as kinase inhibitors

Compounds represented by formula (Ia) or (Ib) and wherein R and Rare as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

Substituted pyrrolo-pyrazole derivatives as kinase inhibitors

Growing community of inventors

Pavia, Italy

Paolo Pevarello